Timolol + BimatoprostThird Party Manufacturing in India

Timolol + Bimatoprost is a fixed-dose combination ophthalmic solution that lowers intraocular pressure through two complementary mechanisms. Bimatoprost is a synthetic prostamide analogue that increases the outflow of aqueous humour through both the trabecular meshwork and uveoscleral pathways. It mimics the action of naturally occurring prostaglandins, binding to FP receptors in the ciliary muscle and sclera to enhance drainage of fluid from the eye. This dual-pathway effect makes it one of the most effective drug classes for lowering IOP. Timolol is a non-selective beta-adrenergic receptor blocker that reduces the production of aqueous humour by the ciliary body. By inhibiting beta-1 and beta-2 receptors in the ciliary epithelium, it decreases cyclic AMP levels and slows the rate of fluid secretion. Together, the combination addresses the two main determinants of intraocular pressure: how much fluid is produced and how efficiently it drains. This dual mechanism provides superior IOP reduction compared to either agent alone, with the convenience of once-daily dosing.

Therapeutic Uses

Timolol + Bimatoprost ophthalmic solution is prescribed for the management of elevated intraocular pressure:

• Open-Angle Glaucoma: First-line combination therapy for patients insufficiently controlled on monotherapy
• Ocular Hypertension: For patients with elevated IOP without optic nerve damage who require pressure reduction
• Adjunctive Therapy: When single-agent therapy with either a prostaglandin analogue or a beta-blocker fails to achieve target IOP
• Patients Requiring Once-Daily Dosing: The fixed combination improves compliance compared to separate administration of two drops

Why Manufacturers Choose Timolol + Bimatoprost

Timolol + Bimatoprost is one of the most prescribed fixed-dose combination eye drops in ophthalmology. The glaucoma market is large and growing with an aging population, and this combination competes with the global brand Ganfort. Indian manufacturers benefit from high prescription volumes in both domestic and regulated export markets. The 5ml ophthalmic solution formulation requires sterile manufacturing with aseptic filling capabilities, creating a barrier to entry that supports pricing power.